Nikko Asset Management Americas’s Sarepta Therapeutics SRPT Stock Holding History

Nikko Asset Management Americas’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-192,650	Closed	-$14.4M	–	222
2021 Q1	$14.4M	Buy	192,650 +109,226	+131%	+$10.1M	0.07%	121
2020 Q4	$14.2M	Buy	83,424 +26,886	+48%	+$3.98M	0.08%	115
2020 Q3	$7.63M	Sell	56,538 -5,463	-9%	-$830K	0.07%	123
2020 Q2	$9.63M	Sell	62,001 -47,334	-43%	-$6.44M	0.13%	85
2020 Q1	$10.7M	Sell	109,335 -12,520	-10%	-$1.43M	0.2%	78
2019 Q4	$15.7M	Sell	121,855 -2,768	-2%	-$279K	0.25%	78
2019 Q3	$9.39M	Buy	124,623 +37,131	+42%	+$4.39M	0.17%	95
2019 Q2	$13.3M	Buy	87,492 +44,061	+101%	+$5.35M	0.26%	79
2019 Q1	$5.18M	Buy	+43,431	New	+$5.58M	0.14%	107

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nikko Asset Management Americas's SRPT Position: Q2 2021 in Review

Nikko Asset Management Americas sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 192,650 shares — an estimated $14.4M sold.

Nikko Asset Management Americas first reported a position in SRPT in Q1 2019 and held it in 9 quarters. The position peaked at $15.7M in Q4 2019. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Nikko Asset Management Americas reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Nikko Asset Management Americas sold 192,650 Sarepta Therapeutics shares in Q2 2021, an estimated $14.4M.
Nikko Asset Management Americas first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 9 quarters.
Nikko Asset Management Americas's Sarepta Therapeutics position peaked at $15.7M in Q4 2019.
330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Nikko Asset Management Americas's 13F filing for Q2 2021, filed 9 Aug 2021.